A large review of 99 studies looked at how different medications, known as b/tsDMARDs, affect life for people with rheumatoid arthritis. These include Janus kinase inhibitors, IL-6 inhibitors, and tumor necrosis factor inhibitors. The study focused on patient reports regarding pain, fatigue, physical health, and mental health.
The findings show that Janus kinase inhibitors and IL-6 inhibitors were more effective at reducing activity limitations than tumor necrosis factor inhibitors. Additionally, the drug rituximab was ranked best overall among the group of medications studied. In terms of mental health specifically, IL-6 inhibitors received the highest ranking.
Patients diagnosed with rheumatoid arthritis for less than three years or those starting with worse symptoms saw larger improvements in their reported outcomes. Because this study involved many different types of comparisons and settings, the results should be viewed as a guide for doctors. Talk to your rheumatologist to see which specific treatment fits your personal health goals.
